FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313590948> ?p ?o ?g. }

• W4313590948 endingPage "21" @default.
• W4313590948 startingPage "21" @default.
• W4313590948 abstract "(1) Background: COVID-19 vaccination in Brazil has been performed mostly with CoronaVac (Sinovac), ChAdOx1-S (AstraZeneca-University of Oxford) and BNT162b2 (Pfizer-BioNTech) vaccines. The titers of IgG antibodies reactive to the SARS-CoV-2 spike protein correlate with vaccine efficacy. Studies comparing vaccine immunogenicity in a real-world scenario are lacking. (2) Methods: We performed a population-based study to analyze the immunoglobulin G response to different COVID-19 vaccines. Citizens older than 18 years (n = 2376) provided personal data, a self-declaration of any previous COVID-19 positive tests and information regarding COVID-19 vaccination: the vaccine popular name and the date of each dose. Blood samples were collected and the levels of IgG reactive to SARS-CoV-2 antigens were determined and compared between different vaccine groups. (3) Results: The seroconversion for anti-spike IgG achieved > 95% by February 2022 and maintained stable until June 2022. Higher anti-spike IgG titers were detected in individuals vaccinated with BNT162b2, followed by ChAdOx1-S and CoronaVac. The anti-spike IgG response was negatively correlated with age and interval after the second dose for the BNT162b2 vaccine. Natural infections boosted anti-spike IgG in those individuals who completed primary vaccination with ChAdOx1-S and CoronaVac, but not with BNT162b2. The levels of anti-spike IgG increased with the number of vaccine doses administered. The application of BNT162b2 as a 3rd booster dose resulted in high anti-spike IgG antibody titers, despite the type of vaccine used during primary vaccination. (4) Conclusions: Our data confirmed the effectiveness of the Brazilian vaccination program. Of the vaccines used in Brazil, BNT162b2 performed better to elicit anti-spike protein IgG after primary vaccination and as a booster dose and thus should be recommended as a booster whenever available. A continuous COVID-19 vaccination program will be required to sustain anti-spike IgG antibodies in the population." @default.
• W4313590948 created "2023-01-06" @default.
• W4313590948 creator A5001166867 @default.
• W4313590948 creator A5001284090 @default.
• W4313590948 creator A5009255990 @default.
• W4313590948 creator A5010151787 @default.
• W4313590948 creator A5011922257 @default.
• W4313590948 creator A5013596488 @default.
• W4313590948 creator A5015412797 @default.
• W4313590948 creator A5016596479 @default.
• W4313590948 creator A5019348889 @default.
• W4313590948 creator A5024022619 @default.
• W4313590948 creator A5037658821 @default.
• W4313590948 creator A5038417416 @default.
• W4313590948 creator A5048085876 @default.
• W4313590948 creator A5058623950 @default.
• W4313590948 creator A5063324856 @default.
• W4313590948 creator A5063638955 @default.
• W4313590948 creator A5075342084 @default.
• W4313590948 creator A5079569739 @default.
• W4313590948 date "2022-12-22" @default.
• W4313590948 modified "2023-09-27" @default.
• W4313590948 title "Population-Based Analysis of the Immunoglobulin G Response to Different COVID-19 Vaccines in Brazil" @default.
• W4313590948 cites W3092136311 @default.
• W4313590948 cites W3111255098 @default.
• W4313590948 cites W3111590711 @default.
• W4313590948 cites W3125933764 @default.
• W4313590948 cites W3153508314 @default.
• W4313590948 cites W3159427996 @default.
• W4313590948 cites W3174017401 @default.
• W4313590948 cites W3176668337 @default.
• W4313590948 cites W3178010802 @default.
• W4313590948 cites W3186114398 @default.
• W4313590948 cites W3188916647 @default.
• W4313590948 cites W3190750829 @default.
• W4313590948 cites W3198636245 @default.
• W4313590948 cites W3217661335 @default.
• W4313590948 cites W4206079892 @default.
• W4313590948 cites W4206906464 @default.
• W4313590948 cites W4210308999 @default.
• W4313590948 cites W4210844692 @default.
• W4313590948 cites W4211259701 @default.
• W4313590948 cites W4214638385 @default.
• W4313590948 cites W4221072241 @default.
• W4313590948 cites W4223966892 @default.
• W4313590948 cites W4224277375 @default.
• W4313590948 cites W4283757321 @default.
• W4313590948 cites W4285602634 @default.
• W4313590948 cites W4285745330 @default.
• W4313590948 doi "https://doi.org/10.3390/vaccines11010021" @default.
• W4313590948 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36679871" @default.
• W4313590948 hasPublicationYear "2022" @default.
• W4313590948 type Work @default.
• W4313590948 citedByCount "0" @default.
• W4313590948 crossrefType "journal-article" @default.
• W4313590948 hasAuthorship W4313590948A5001166867 @default.
• W4313590948 hasAuthorship W4313590948A5001284090 @default.
• W4313590948 hasAuthorship W4313590948A5009255990 @default.
• W4313590948 hasAuthorship W4313590948A5010151787 @default.
• W4313590948 hasAuthorship W4313590948A5011922257 @default.
• W4313590948 hasAuthorship W4313590948A5013596488 @default.
• W4313590948 hasAuthorship W4313590948A5015412797 @default.
• W4313590948 hasAuthorship W4313590948A5016596479 @default.
• W4313590948 hasAuthorship W4313590948A5019348889 @default.
• W4313590948 hasAuthorship W4313590948A5024022619 @default.
• W4313590948 hasAuthorship W4313590948A5037658821 @default.
• W4313590948 hasAuthorship W4313590948A5038417416 @default.
• W4313590948 hasAuthorship W4313590948A5048085876 @default.
• W4313590948 hasAuthorship W4313590948A5058623950 @default.
• W4313590948 hasAuthorship W4313590948A5063324856 @default.
• W4313590948 hasAuthorship W4313590948A5063638955 @default.
• W4313590948 hasAuthorship W4313590948A5075342084 @default.
• W4313590948 hasAuthorship W4313590948A5079569739 @default.
• W4313590948 hasBestOaLocation W43135909481 @default.
• W4313590948 hasConcept C126322002 @default.
• W4313590948 hasConcept C159047783 @default.
• W4313590948 hasConcept C159654299 @default.
• W4313590948 hasConcept C203014093 @default.
• W4313590948 hasConcept C22070199 @default.
• W4313590948 hasConcept C2777451964 @default.
• W4313590948 hasConcept C2779134260 @default.
• W4313590948 hasConcept C2780868878 @default.
• W4313590948 hasConcept C2780898057 @default.
• W4313590948 hasConcept C2908647359 @default.
• W4313590948 hasConcept C2909509916 @default.
• W4313590948 hasConcept C3008058167 @default.
• W4313590948 hasConcept C32611913 @default.
• W4313590948 hasConcept C524204448 @default.
• W4313590948 hasConcept C71924100 @default.
• W4313590948 hasConcept C99454951 @default.
• W4313590948 hasConceptScore W4313590948C126322002 @default.
• W4313590948 hasConceptScore W4313590948C159047783 @default.
• W4313590948 hasConceptScore W4313590948C159654299 @default.
• W4313590948 hasConceptScore W4313590948C203014093 @default.
• W4313590948 hasConceptScore W4313590948C22070199 @default.
• W4313590948 hasConceptScore W4313590948C2777451964 @default.
• W4313590948 hasConceptScore W4313590948C2779134260 @default.
• W4313590948 hasConceptScore W4313590948C2780868878 @default.

• next